PRAME-targeted NK cells for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a specific genetic marker called HLA-A*02:01 (your doctor can check with a blood test).
- Your melanoma must have come back or not responded to standard immunotherapy treatments like Keytruda or Opdivo.
- You need to be in fairly good health, able to care for yourself and do light activity (ECOG score 0 or 1).
- You must have measurable tumors and adequate organ function (heart, lungs, kidneys).
- You cannot be pregnant or breastfeeding, and must agree to use birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
This trial tests an experimental drug, IMC-P115C, for people with advanced cancers that have a specific marker called PRAME and a genetic type HLA-A*02:01. It may be an option if other treatments have stopped working or caused side effects.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests engineered immune cells (CAR-NK cells) designed to target two markers found on melanoma cells. The goal is to help patients with melanoma that has spread or cannot be surgically removed and has not responded to or is unsuitable for standard treatments.
This trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to standard immunotherapy. It uses your own immune cells to fight the cancer.
Hear when a new Phase 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.